Does alfacalcidol reduce cardiovascular complications in hemodialysis patients?

Cardiovascular disease is a major health burden in chronic kidney disease (CKD) populations. Indeed, individuals with end-stage renal disease (ESRD) have a 6 to 8-fold increase in mortality compared to the general population, half of which is caused by cardiovascular disease (1). The mineral and bone disorder of CKD (CKD-MBD), which also includes vascular calcification, contributes to these cardiovascular complications (2).